Biotinyl-6-aminocaproic acid n-hydroxysuccinimide ester (biotin-X-NHS) is a heterobifunctional crosslinker that combines biotin, a vitamin known for its role in metabolic processes, with an N-hydroxysuccinimide (NHS) ester. This molecule is widely used in research for various applications, including protein labeling and immobilization. The NHS ester group reacts readily with primary amines on proteins, creating a stable amide bond. This reaction allows for the specific attachment of biotin to proteins, which can then be used for downstream applications like affinity purification, detection, and tracking. Biotin-X-NHS is frequently employed in a variety of research fields, including biochemistry, cell biology, and molecular biology, to study protein interactions, localization, and dynamics. The synthesis of biotin-X-NHS typically involves a multi-step process that starts with the activation of the carboxylic acid group of 6-aminocaproic acid with a suitable coupling reagent, followed by reaction with biotin. The resulting biotin-6-aminocaproic acid intermediate is then further reacted with N-hydroxysuccinimide to form the desired biotin-X-NHS.'
```
biotinyl-6-aminocaproic acid N-hydroxysuccinimide ester: reagent for preparing biotin-labeled nucleosides; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 83874 |
| SCHEMBL ID | 309059 |
| MeSH ID | M0139720 |
| Synonym |
|---|
| 72040-63-2 |
| biotinamidohexanoic acid n-hydroxysuccinimide ester |
| nhs-lc-biotin |
| biotinamidohexanoic acid n-hydroxysuccinimide ester, >=98% (tlc), powder |
| bachs |
| succinimidyl-6-biotinamide hexanoate |
| (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate |
| succinimidyl 6-(biotinamido)hexanoate |
| n-biotinyl-epsilon-aminocaproic acid n-hydroxysuccinimide ester |
| biotinyl-epsilon-aminohexanoic acid n-hydroxysuccinimide ester |
| biotin-amidocaproate-n-hydroxysuccinimide ester |
| biotinyl-6-aminocaproic acid n-hydroxysuccinimide ester |
| 1h-thieno(3,4-d)imidazole-4-pentanamide, n-(6-((2,5-dioxo-1-pyrrolidinyl)oxy)-6-oxohexyl)hexahydro-2-oxo-, (3as-(3aalpha,4beta,6aalpha))- |
| 1h-thieno(3,4-d)imidazole-4-pentanamide, n-(6-((2,5-dioxo-1-pyrrolidinyl)oxy)-6-oxohexyl)hexahydro-2-oxo-, (3as,4s,6ar)- |
| (+)-biotinamidocaproate n-hydroxysuccinimidyl ester |
| n-(+)-biotinyl-6-aminocaproic acid n-succinimidyl ester |
| succinimidyl-6-(biotinamido) hexanoate |
| n-(+)-biotinyl-6-aminohexanoic acid nhs ester |
| AKOS015899868 |
| biotin-lc-nhs ester |
| BP-22108 |
| SCHEMBL309059 |
| 2,5-dioxopyrrolidin-1-yl 6-(5-((3as,4s,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl)pentanamido)hexanoate |
| biotinamidocaproate n-hydroxysuccinimidyl ester |
| W-203622 |
| n-[5-(n-succinimidyloxycarbonyl)pentyl]biotinamide |
| 6-biotinamidohexanoic acid n-succinimidyl ester |
| S0490 |
| n-biotinyl-6-aminohexanoic acid succinimidyl ester |
| (+)-biotin-lc-nhs ester |
| GS-5694 |
| 2,5-dioxopyrrolidin-1-yl 6-{5-[(3as,4s,6ar)-2-oxo-hexahydro-1h-thieno[3,4-d]imidazol-4-yl]pentanamido}hexanoate |
| n-(+)-biotinyl-6-aminocaproic acid succinimidyl ester |
| UVGHPGOONBRLCX-NJSLBKSFSA-N |
| biotin-x, succinimidyl ester |
| lc-nhs-(+)-biotin |
| DTXSID90992728 |
| n-{6-[(2,5-dioxopyrrolidin-1-yl)oxy]-6-oxohexyl}-5-(2-hydroxy-3a,4,6,6a-tetrahydro-1h-thieno[3,4-d]imidazol-6-yl)pentanimidic acid |
| AMY2477 |
| HY-135915 |
| CS-0116277 |
| biotin-c5-nhs ester |
| biotinamidohexanoic acid n-hydroxysuccinimide ester; n-succinimidyl n-biotinyl-6-aminocaproate; n-(+)-biotinyl-6-aminocaproic acid n-succinimidyl ester; (+)-biotinamidocaproate n-hydroxysuccinimidyl ester;2,5-dioxopyrrolidin-1-yl 6-(5-((3as,4s,6ar)-2-oxoh |
| A866331 |
| F11364 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.09) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||